Milestone Pharmaceuticals Inc. (MIST) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Montreal, QC, 加拿大. 现任CEO为 Joseph G. Oliveto.
MIST 拥有 IPO日期为 2019-05-09, 33 名全职员工, 在 NASDAQ Global Select, 市值为 $174.35M.
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
